TNF and inflammatory bowel disease: Since 1990s, when the anti-TNF agents (infliximab, adalimumab) were approved for the treatment of IBD, the armamentarium has been expanded with novel biologic therapies and molecules, including the anti-interleukin-12/23 ustekinumab and the gut-selective anti-α4β7-integrin vedolizumab [2].